ArticleThe Lancet regional health. Southeast Asia2025
Incidence patterns of rare cancer in southeast Asian and western Pacific countries (RARECAREnet Asia project): a study using population-based cancer registry data, 2011-2015.
Article in The Lancet regional health. Southeast Asia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In Southeast Asia (SEA), the understanding of most rare cancers is limited, which sometimes leads to delays in diagnosis, treatment, and care. This study aimed to estimate for the first time the incidence of rare cancers in SEA using population-based cancer registry (PBCR) data from the 2011-2015 period. Methods: This study used data from the nationwide PBCR of Malaysia and two PBCRs in northern Thailand in Chiang Mai and Lampang Cancer registries. The age-standardized incidence rate (ASR) per 100,000 person-year of the rare cancers included in the RARECAREnet list was calculated. All analyses were performed using SEER∗Stat (version 8.3.5). Cancers defined as rare by RARECAREnet in Europe were also rare in Thailand and Malaysia. Findings: The ASR of some rare cancers in Thailand and Malaysia were greater than that in Japan, Korea, and Taiwan, including some pediatric cancers (pancreatoblastoma and odontogenic malignant tumors) in Malaysia, eye and adnexal cancer, and epithelial tumors of the penis in Thailand. ASR of nasopharyngeal cancer was higher in Thailand and Malaysia than in Japan and Korea but lower compared to Taiwan. Interpretation: Although most rare cancers were also rare in Thailand and Malaysia, some cancers were not considered rare. However, the incidence of some rare cancers in Thailand and Malaysia were higher than that in Japan, Korea, and Taiwan. To enhance understanding, diagnosis, treatment, and care of rare cancers, reliable epidemiological data needs to be generated under the RARECAREnet Asia project by working with countries in Asia with high-quality PBCRs. Funding: This study was supported by a UICC Yamagiwa-Yoshida Memorial International Cancer Study Grant (Award/Grant Number: YY/2022-1477) and Government of Japan Ministry of Health Labour and Welfare Grant numbers: 23EA1033, and was partially supported by Chiang Mai University, Thailand.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.